

Rebyota™ to require prior authorization for Medicare Advantage members starting March 1

For dates of service on or after March 1, 2023, the following drug will require prior authorization for Medicare Plus Blue and BCN Advantage members. This drug is part of members' medical benefits, not their pharmacy benefits.

- Rebyota (fecal microbiota, live-*jslm*), HCPCS code J3590

Submit prior authorization requests through the NovoLogix[®] online tool.

When prior authorization is required

Rebyota will require prior authorization when it's administered by a health care provider in sites of care such as outpatient facilities or physician offices and is billed in one of the following ways:

- Electronically through an 837P transaction or on a professional CMS-1500 claim form
- Electronically through an 837I transaction or using the UB04 claim form for a hospital outpatient type of bill 013x

Submit prior authorization requests through the NovoLogix tool

To access NovoLogix, log in to our provider portal (availity.com*), click *Payer Spaces* in the menu bar and then click the BCBSM and BCN logo. You'll find links to the NovoLogix tools on the Applications tab.

Note: If you need to request access to our provider portal, follow the instructions on the [Register for webtools](https://bcbsm.com/providers) webpage on bcbsm.com/providers.

List of requirements

For a list of requirements related to drugs covered under the medical benefit, see the [Medical Drug and Step Therapy Prior Authorization List for Medicare Plus Blue PPO and BCN Advantage members](#).

We'll update the list to reflect this change prior to the effective date.

*Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're not responsible for its content.

Availity[®] is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.